Grants per year
Personal profile
Research Interests
I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.
Training Experience
| 2011 | Residency, Case Western Reserve University Hospital |
| 2014 | Fellowship, New York University Medical Center |
Education/Academic qualification
MD, Michigan State University
… → 2008
MS, Michigan State University
… → 2003
Research interests
- Cancer of Unknown Primary
- Clinical Research
- Drug Discovery
- Melanoma
- Skin Cancer
Fingerprint
Dive into the research topics where Sunandana Chandra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
-
Prot #OMS-I103: The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressin
Precision Oncology, LLC, OncoSec Medical Incorporated
7/1/20 → 7/1/23
Project: Research project
-
Prot #AST-008-102: A Phase 1b/2 Study of AST-008 Combined with Pembrolizumab in Patients with Advanced Solid Tumors
MS Clinical Services, LLC, Exicure, Inc.
4/6/20 → 4/30/21
Project: Research project
-
Prot #R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
ICON Clinical Research Limited, Regeneron Pharmaceuticals, Inc.
2/25/20 → 2/25/23
Project: Research project
-
Prot #R2810-ONC-1806: Cemiplimab Survivorship Epidemiology (CASE) Study
inVentiv Health Clinical, Regeneron Pharmaceuticals, Inc.
12/5/19 → 12/5/22
Project: Research project
Research Output
-
A phase ii study of glembatumumab vedotin for metastatic uveal melanoma
Hasanov, M., Rioth, M. J., Kendra, K., Hernandez-Aya, L., Joseph, R. W., Williamson, S., Chandra, S., Shirai, K., Turner, C. D., Lewis, K., Crowley, E., Moscow, J., Carter, B. & Patel, S., Aug 2020, In: Cancers. 12, 8, p. 1-12 12 p., 2270.Research output: Contribution to journal › Article › peer-review
Open Access -
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
Migden, M. R., Chandra, S., Rabinowits, G., Chen, C. I., Desai, J., Seluzhytsky, A., Sasane, M., Campanelli, B., Chen, Z., Freeman, M. L., Ibrahim, S. F., Khushalani, N. I., Andria, M. & Ruiz, E., 2020, In: Future Oncology. 16, 4, p. 11-19 9 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Najjar, Y. G., Navrazhina, K., Ding, F., Bhatia, R., Tsai, K., Abbate, K., Durden, B., Eroglu, Z., Bhatia, S., Park, S., Chowdhary, A., Chandra, S., Kennedy, J., Ernstoff, M., Vachhani, P., Drabick, J., Singh, A., Xu, T., Yang, J., Carvajal, R. & 7 others, , Jun 1 2020, In: Journal for immunotherapy of cancer. 8, 1Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Ribas, A., Algazi, A., Ascierto, P. A., Butler, M. O., Chandra, S., Gordon, M., Hernandez-Aya, L., Lawrence, D., Lutzky, J., Miller, W. H., Campbell, K. M., Delafont, B., Marshall, S., Mueller, N. & Robert, C., Dec 2020, In: Nature communications. 11, 1, 6262.Research output: Contribution to journal › Article › peer-review
Open Access -
Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy
Chandra, S., Zheng, Y., Pandya, S., Yu, T., Kearney, M., Wang, L., Kim, R. & Phatak, H., Nov 2020, In: Future Oncology. 16, 31, p. 2521-2536 16 p.Research output: Contribution to journal › Article › peer-review
Open Access